New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone

American Heart Journal

Volumn 144, Issue 5 SUPPL., 2002, Pages

  Funder, John W ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; DEOXYCORTICOSTERONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; MINERALOCORTICOID RECEPTOR; OXPRENOATE POTASSIUM; PLACEBO; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; SODIUM CHLORIDE; SPIRONOLACTONE;

ANIMAL CELL; ANIMAL MODEL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HEART FAILURE; HUMAN; HYPERALDOSTERONISM; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SWINE; TREATMENT OUTCOME;

EID: 0036847322     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2002.129971     Document Type: Conference Paper

References (17)

1. Okubo S, Niimura F, Nishimura H, et al. Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion. J Clin Invest 1997;99:855-60.
2. Krozowski ZS, Funder JW. Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intrinsic steroid specificity. Proc Natl Acad Sci USA 1983;80:6056-60.
3. Pearce P, Funder JW. High affinity aldosterone binding sites (type I receptors) in rat heart. Clin Exp Pharmacol Physiol 1987;14:859-66.
4. Arriza JL, Weinberger C, Cerelli G, et al. Cloning of human mineralocorticoid receptor complementary DNA: Structural and functional kinship with the glucocorticoid receptor. Science 1987;237:268-75.
5. Funder JW, Pearce PT, Smith R, et al. Mineralocorticoid action: Target tissue specificity is enzyme, not receptor, mediated. Science 1988;242:583-5.
6. Edwards CRW, Stewart PM, Burt D, et al. Localisation of 11β-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor. Lancet 1988;2:986-9.
7. Gomez-Sanchez EP, Fort C, Thwaites D. Central mineralocorticoid receptor antagonism blocks hypertension in Dahl S/JR rats. Am J Physiol 1992;262:E96-9.
8. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 1992;120:893-901.
9. Young M, Head G, Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol 1995;269:E657-62.
10. Sato A, Funder JW. High glucose stimulates aldosterone-induced hypertrophy via type I mineralocorticoid receptors in neonatal rat cardiomyocytes. Endocrinology 1996;137:4145-53.
11. Fujisawa G, Dilley R, Fullerton MJ, et al. Experimental cardiac fibrosis: Differential time course of responses to mineralocorticoid-salt administration. Endocrinology 2001;142:3625-31.
12. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
13. Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the randomized aldactone evaluation study (RALES). Circulation 2000;102:2700-6.
14. Rocha R, Stier CT Jr. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab 2001;12:308-14.
15. Rocha R, Stier CT Jr, Kifor I, et al. Aldosterone: A mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000;141:3871-8.
16. Rocha R, Rudolph AE, Frierdich GG, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol. 2002;283:1802-10.
17. Ward MR, Kanellakis P, Ramsey D, et al. Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation 2001;104:467-72.